ASX Announcement

07 August 2025

Release of Investor Webinar Presentation

OncoSil Medical Limited (ASX:OSL) ("OSL" or "the Company") is pleased to release the following investor webinar presentation to the market.

The presentation covers both the Company's achievements over the latter part of its recently completed 2025 financial year and commercialisation milestones expected to be delivered over the coming year, including:

- Drivers behind the record OncoSil™ dose sales in Q4 FY25
- An update on OncoSil Medical's ongoing efforts to grow its geographic footprint, including some discussion on new regions being targeted (the US included)
- The steady stream of studies demonstrating superior outcomes from usage of the OncoSil™ device
- An explanation of the OncoSil™ device clinical study soon to be undertaken by the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA)
- Where the proceeds from the recent $8.7m (before costs) capital raise will be directed.

Ends.

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: Nigel.lange@oncosil.com T: +49 16096424981	**Ms. Olga Smejkalova** Company Secretary E: o.smejkalova@acclime.com	**Ms. Julia Maguire** **The Capital Network** Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338

About OncoSil Medical Limited (ASX:OSL)

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year1. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel.

To learn more, please visit: www.oncosil.com/

OSL Update

August 2025

Nigel Lange, CEO & Managing Director

Targeted Approach • Positive Impact

ASX Code: OSL

Disclaimer

This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (**OncoSil, OSL** or the **Company**) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the information contained should be read in conjunction with past and future ASX announcements made by OncoSil and should not be relied upon as an independent source of information. Please contact OncoSil and/or refer to the Company's website www.oncosil.com for further information.

Not an Offer for Securities

Nothing in this Presentation constitutes investment advice or should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in the Company, in any jurisdiction.
This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require for evaluating OSL, its assets, possible valuation, prospects or potential opportunities. Please note that the information contained herein is only of a general nature. It should NOT be relied upon for any evaluation of OSL or for making any investment decision. This presentation does NOT constitute a “Prospectus" or a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this presentation should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of law. Please refer to the international offer restrictions section of this presentation.

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or in any jurisdiction in which such offer would be illegal. The New Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold , directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Forward-Looking Statements

This document contains certain forward-looking statements as at the date of this presentation relating to OncoSil’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other national and international authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales, nor that that any specific objective of the Company will be achieved or that any particular performance of the Company or of its shares will be achieved.
In particular, the Company's expectations regarding the approval and commercialisation of the product candidates could be affected by, amongst other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; changes in legislation or regulatory requirements, our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our Company, products, product candidates, financial results and business prospects. Should one or more of these changes, risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined herein. You are urged to consider all of the above and advice from your own advisers carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The information in this presentation is not financial product advice, is not an offer to invest in the securities of OncoSil and does not take into account your investment position or objectives, financial situation or any particular requirements. For these and other reasons, you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Disclaimer

This Presentation and any supplemental materials have been prepared by OncoSil based on available information. Although reasonable care has been taken to ensure the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, or correctness of such information and opinions and no reliance should be placed on such information or opinions. The Company is not obliged to advise of changes or provide updates to any such materials. To the maximum extent permitted by law, none of OncoSil or any of its members, directors, officers, employees, or agents or corporate advisors, nor any other person accepts any liability whatsoever for any loss, however arising, from the use of the presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability arising from fault or negligence on the part of OncoSil or any of its directors, officers, employees or agents. Neither OncoSil nor any other entity or person in or associated with OncoSil guarantees any return (whether capital or income) or generally the performance of OncoSil or the price at which its securities may trade.

Past performance of the Company cannot be assumed as indicative of the future performance. There is NO guarantee of future performance - actual results and future outcomes will in all likelihood differ from those outlined in this presentation.

All dollar values are in Australian dollar ($A) terms unless otherwise stated. Figures in this presentation are subject to rounding. The information contained in this presentation is current as of August 7, 2025

Executive Summary

Commercialising targeted radiotherapy for pancreatic cancer

- OncoSil Medical is commercialising the OncoSil™ device, an implanted device (brachytherapy) delivering targeted radiation (^{32}P) to pancreatic tumours –
- OncoSil™ device is now **approved for sale in over 34 countries** via CE Mark
- **Commercial ramp-up expected in FY26** and beyond following newly added markets and near-term market entry expectations
- **Increasing market access** via label expansion combining new delivery methods and new chemotherapy combinations[1]
- **Accelerating market penetration** with a shortened sales cycle and an increase in addressable hospital sites in the EU and UK
- **Platform technology** can be leveraged into other cancer indications (bile duct cancer, liver, glioblastoma)
- Experienced Board & Management team in the commercialisation of radiotherapies

>US$4.2bn global addressable market with no competition[4]

- Granted **Breakthrough Designation** in the EU, UK and US with extensive **patent coverage** across all key geographies
- Large global pancreatic cancer patient population of ~510k p.a and targeting locally unresectable population of ~153k (~30%) with the **market expected to increase by 37% by 2035**[2]
- Negligible survival improvement in over 20 years with <12% survival rates at 5-years and 8.5 months Median Overall Survival
- **First ever Comparative analysis published May 2025 indicates significant benefit in combination with Chemotherapy:**[3]
  - ✓ ***Overall Survival benefit of >7 months*** *– 20.0 months survival of OncoSil™ + chemotherapy vs. 12.3 months in chemotherapy alone*
  - ✓ ***More than doubled surgical resection rate*** *– 28.6% in Oncosil™ + chemotherapy vs. 12.1% in chemotherapy alone*
  - ✓ ***More than doubled patients downstaged*** *– 31.4% in Oncosil™ + chemotherapy vs. 13.6% in chemotherapy alone*
  - ✓ **Second Comparative Analysis presented May-25 confirms superiority for OncoSil™ + chemotherapy *vs.* chemotherapy + SBRT** [5]

Attractive unit economics

- Indicative ~US$24k per device with Gross Margin expansion expected to increase from 50% to 65% in CY26 and target of >75% expected at scale
- **Cost-out initiatives driving lower fixed cost base (20% reduction)** with significant opportunity for operating leverage over the medium term
- **Negligible additional capex** required

References: 1. Subject to Regulatory Approval. 2. Globocan 2022 data. 3. Lim A et al. Combined phosphorus-32 implantation and chemotherapy alone for locally advanced pancreatic cancer: a propensity-score weighted landmark analysis. *Gastrointest Endosc* 2025 May 8. 4. 179,000 global locally advanced pancreatic cancer population multiplied by US$24k average price. 5. Lim A et al. Comparison of combined chemotherapy and stereotactic body radiation therapy with combined chemotherapy and phosphorus-32 microparticle intra-tumoural implantation in patients with locally advanced pancreatic adenocarcinoma. Presented at Digestive Disease Week (DDW2025) scientific meeting in San Diego, USA, 3–6 May 2025.

Executive Summary

Significant recent achievements

- ✓ Received MDR approval and UKCA Certificate which includes the removal of all existing post-market restrictions in Europe and The UK (OSPREY registry) – reducing hospital customers friction and accelerating adoption
- ✓ 100% Recruitment achieved in landmark PANCOSIL study (a groundbreaking delivery method for OncoSil™ device)
- ✓ 100% Recruitment achieved in TRIPP-FFX study (to expand OncoSil™ device label with additional chemotherapy combinations)
- ✓ New distribution agreements in Gulf Region, Egypt and Nordic countries
- ✓ Constructive discussions with US FDA regarding the approval pathway for OncoSil™ device in Bile Duct Cancer (dCCA)
- ✓ Received German Federal Joint Committee (G-BA) approval and conditional reimbursement across 120 hospitals in Germany. Tender announced by G-BA – now into second round short list.
- ✓ Filing for TGA submission completed in 2Q CY25

Catalyst rich CY25/26

- At commercial ramp up in existing markets including Greece, Israel, Italy, Spain, Turkey,
- Accelerating commercial activities via expanded market access and geographical opportunities including:
  - *Distribution agreements or direct representation in key markets including Argentina, Brazil, Chile, France, South Korea, South East Asia, Switzerland*[1]
  - *Label expansion to include delivery method for a new medical speciality, Interventional Radiology (PANCOSIL study) – anticipated commercial availability late Q4 CY25*
- First Commercial production in Sydney Manufacturing facility (anticipated late Q4 CY25)
- OncoSil device to be commercially available to interventional radiologists (anticipated late Q4 CY25)
- TGA approval (anticipated Q4 CY25)
- Commercial launch in Gulf Regions (anticipated H1 CY26)

Equity raising

- Equity raising completed
  - Two-tranche institutional placement of $6,7M
  - Share purchase plan $2,0M (oversubscribed by $2.4M)
  - 1 for 400 share consolidation completed prior to equity raise

References: **1.** Subject to Regulatory Approval. **2.** United European Gastroenterology. Pancreatic Cancer Across Europe: Taking a united stand. https://ueg.eu/files/771/b7ee6f5f9aa5cd17ca1aea43ce848496.pdf. **3.** Lim A et al. Combined phosphorus-32 implantation and chemotherapy: A comparison with standard therapy using a propensity-score weighted landmark analysis and an assessment of its impact on vascularity in locally advanced pancreatic cancer. Presented at the Gastroenterological Society of Australia's Australian Gastroenterology Week (AGW 24) Meeting; 14–16 September 2024. Journal of Gastroenterology and Hepatology 2024; 39 (Suppl. 1): 39 Abs, 337.

Pancreatic Cancer Prognosis has Remained Unchanged for 40 Years[1]



Survival rates are very poor:

- 8.5 months overall median survival
- <12% reach 5-year survival[2]
- Lower survival rate than any other cancer[3]
- The number of cases and deaths both estimated to increase by 40% before 2035[3]

New therapeutic options urgently needed

References: 1. Cancer Research UK. www.cancerresearchuk.org/health-professional/cancer-statistics/survival/common-cancers-compared#heading-Three (accessed September 2024).
2. American Cancer Society. Cancer Facts & Figures 2023. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf. 3. United European Gastroenterology. Pancreatic Cancer Across Europe: Taking a united stand. https://ueg.eu/files/771/b7ee6f5f9aa5cd17ca1aea43ce848496.pdf.

Pancreatic Cancer Stage at Diagnosis

Surgical resection remains the only potentially curative treatment for pancreatic cancer[1]



30% of LAPC patients show metastatic progression within 3-6 months[9,10]

Abbreviations: CT: Chemotherapy; ICT: Induction chemotherapy; CCRT: Concurrent chemoradiation therapy.

References: 1. Ducreux M et al. Ann Oncol 2015; 26 (Suppl 5): v56–68. 2. van Dam JL et al. Eur J Cancer. 2022; 160: 140–149. 3. Chang JS et al. Cancer Res Treat 2018; 50: 562–574 (suppl data). 4. Burris HA 3rd et al. J Clin Oncol 1997; 15: 2403–2413. 5. Von Hoff DD et al. N Engl J Med 2013; 369: 1691–1703. 6. Conroy T et al. N Engl J Med 2011; 364: 1817–1825. 7. Balaban EP et al. J Clin Oncol 2016; 34: 2654–2668. 8. National Comprehensive Cancer Network (NCCN) Clinical Practive Guidelines in Oncology: Pancreatic adenocarcinoma. Version 1.2020. 9. Huguet et al. J Clin Oncol 2010. 10. Mukherjee et al, Lancet Oncol 2013.

OncoSil™ Device

Driving increased resection rates, downstaging, survival benefits and quality of life

OncoSil™ is intended for the treatment of **locally advanced unresectable pancreatic cancer,** in combination with gemcitabine-based chemotherapy *(combination with FOLFIRINOX currently in trials)*

OncoSil™ is a **single-use** brachytherapy device comprised of microparticles and a diluent



OncoSil™ is currently implanted directly into a pancreatic tumour via injection under **endoscopic ultrasound** guidance

98% of all radiation is delivered within **81 days** of injection causing damage to cancer cell DNA and **killing malignant cancer cells with no damage to surrounding tissue**

Requires only one supervised procedure given simplicity and familiarity with standard, everyday, biopsy procedures

Percutaneous delivery is transformational and anticipated to significantly accelerate market penetration:

- ✓ Expanding the number of treating clinicians to include Interventional Radiologists
- ✓ Broader patient access and points of care
- ✓ Outpatient day procedure – complete within 20 minutes
- ✓ Conscious sedation (patient awake)

PANCOSIL study anticipated to complete in Q2 CY25 – topline readout in Q3 CY25

Targeting Q4 CY25 to make OncoSil™ commercially available to Interventional Radiologists

Training New Sites to start OncoSil™ treatments



- Training Commenced
- Training Completed and ready to start
- Sites using OncoSil

Commercial Market Expansion

Target Market	Pancreatic Cancer Incidence p.a.[1]	Locally Advanced Pancreatic Cancer[2]	Market Opportunity ($USm)
Existing Priority Markets			
UK	11,852	3,556	~91
Spain	9,282	2,785	~68
Italy	16,111	4,833	~118
Germany	22,587	6,776	~174
Greece	2,343	703	~17
Austria	2,250	675	~17
Turkey	9,012	2,704	~54
Portugal	2,217	665	~16
Israel	1,249	375	~9
Saudi Arabia	666	200	~6
Hong Kong	1,116	335	~8
Egypt	3,649	1,095	~$22
Nordic Region	6,871	2,061	~$50
Total (Existing)	89,205	26,762	~651
Near-Term Target Markets			
South Korea	10,046	3,014	~74
France	16,538	4,961	~122
Brazil	15,383	4,615	~113
Argentina	5,979	1,794	~44
Netherlands	3,689	1,107	~27
South East Asia	13,723	4,117	~101
Others	6,588	1,976	~48
Total (New)	71,946	21,584	~529

OncoSil™ device remains at the early-stage of commercialization in existing geographies with ~US$651m market size (up from US$588m)

Geographies include the Nordic Region and Egypt newly added

Expanding to >US$1.1bn addressable market over next 18 –24 months

Market Penetration expected to now accelerate over the near-term driven by:

- Percutaneous Delivery following a target Q4 CY2025 label expansion

Reference: 1. Globocan 2022 data. 2 Calculated as 30% of Pancreatic Cancer Incidence. 3 Local Price in EUR converted to USD (EURUSD) 1.1133

Accelerating Commercialisation

Compelling cost-benefit proposition with no direct competition

Attractive Unit Economics

- Average list price of ~€22k/~US$24k
- Gross Margin of 50% expected to increase to 65% driven by manufacturing productivity and **targeting >75%** device margins at scale

No direct Competition

- Granted **Breakthrough Designation** in the US, EU, UK
- The **only commercially available, or in development, targeted Radiotherapy for LAPC**
- Patented technology that is difficult to reverse engineer

Capital light operating model

- **Concentrated industry structure** with high volumes undertaken at 'centres of excellence'
- High Return on Capital with relatively **small sales force required** in direct markets to drive adoption
- High operating leverage anticipated through economies of scale in the long-term

Commercial scale manufacturing capability

- **End-to-end manufacturing capabilities** and logistics already in place and able to meet commercial quantities
- Second manufacturing facility (Sydney, Australia) expected to be accretive to Gross Margin and producing first commercial doses in Q4 CY25

Multiple high value initiatives to broaden market access & accelerate commercialisation

- Label expansion to include **additional method of delivery** (PANCOSIL study – Expected completion Q2 CY25
- Label expansion to include **additional chemotherapy combination** (TRIPP-FFX study – expected completion Q2 CY25
- **Expansion into new markets** (Argentina, Brazil, Chile, France, Hong Kong, Sout East Asia, South Korea, Switzerland)

Reference: EURUSD 1.1133 (19 May 2025).

Enhancing Market Access

Program	Description	Key Milestones	Commercial Impact
Bile Duct Cancer	Bile Duct Cancer (Distal Chalingiocarcinoma - dCCA) For approval by US FDA under Human Device Exemption (HDE)	• Discussions remain ongoing and constructive with US FDA • OncoSil is preparing additional data to support HDE application	Small addressable market however a supportive pathway to US market entry for LAPC
G-BA Trial	120 German Hospitals to negotiate reimbursement of the OncoSil™ device under the innovation funding program (NUB). Currently awaiting confirmation from German Public Health Agencies Federal Joint Committee (G-BA)	• G-BA approval received Oct-24 • Procedural finalisation from Ministry of Health Q1 2025 • CRO selection into 2nd round, protocol synopsis and trial design • Expected completion date Q4 CY27	Public insurance reimbursement for OncoSil™ device in Germany for trial participants Opportunity to participating hospitals to receive reimbursement for patients not participating in trial
PANCOSIL	Feasibility and safety of CT-guided percutaneous radionuclide therapy with OncoSil™ device + Chemotherapy in non-progressive locally advanced pancreatic cancer	• 100% recruitment achieved (20/20) • Fully enrolled Q3 CY25 • Regulatory submission target of Q3/4 CY25 – Added to Label - targeted commercial launch in EU and UK markets in Q4 CY25	Accelerates market penetration with lower barriers to adoption via a new method of delivery for a new medical speciality (Interventional Radiology)
TRIPP-FFX	Efficacy and Safety of Oncosil combined with standard Folflirinox chemotherapy *vs.* FOLFIRINOX chemotherapy alone	• 100% recruitment achieved (88/80) • Fully enrolled Q3 CY25 • Target Regulatory submission Q3/4 CY25 • Added to Label in all approved jurisdictions H2 CY26	Accelerates market penetration with label expansion to include coverage of OncoSil™ device with all typical LPAC chemotherapy regimens (EU region)

Upcoming Milestones

Significant commercial catalysts over the next 18 months





References: 1. Indicated in Distal Chalingiocarcinoma. 2. Subject to regulatory Review. 3. Subject to approval following PANCOSIL study.

Leadership Team

Experienced Board and Management

Depth in Nuclear Medicine Commercialisation

Douglas Cubbin
Non-executive Chairman

30+ years' biopharmaceutical experience in senior roles across varied industries.

Had a key role at Telix Pharmaceuticals (ASX:TLX) for +5 yeas, including IPO.

Dr Thomas Duthy
Non-executive Director

20+ years of experience across financial markets, corporate development and board-level roles, involved in numerous successful M&A transactions.

Lel Smits
Non-executive Director

Award-winning entrepreneur, director and investor relations advisor, serving as a Director on Australian Shareholders' Association since 2021.

Nigel Lange
Managing Director & CEO

30+ years' experience in medical device industry.

Served as Group COO and Interim Group CEO of Sirtex Medical (ASX:SRX).

Shelley Steyn
Chief Financial Officer

Extensive experience in senior accounting, commercial and financial analysis, and audit roles across listed and private companies.

Dr Jon Bell MD
Chief Medical Officer

12 years' experience as consultant interventional radiologist and an internationally recognised expert in interventional oncology.

Nigel Lange

CEO & Managing Director

E: nigel.lange@oncosil.com

Learn more about OncoSil Medical:

- Website
- ASX announcements
- LinkedIn

Targeted Approach • Positive Impact